Tezepelumab’s trial results strengthen potential for biomarker-driven biologic therapies in COPD:… EP News Bureau May 20, 2025 GlobalData’s latest analysis reveals that tezepelumab, evaluated in the Phase IIa COURSE trial, achieved a 26 per cent reduction…
Biologic therapies show progress in severe asthma treatment and remission potential GlobalData Nov 26, 2024 Barriers such as cost and accessibility highlight the urgent need for equitable healthcare solutions to ensure widespread adoption…
